Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Low Dose Primaquine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 1 year~* Presentation with a confirmed fever (≥ 38⁰C axilla or ≥ 37.5⁰C aural) or history of fever in previous 48 hours +/- other clinical features of uncomplicated malaria~* Plasmodium falciparum monoinfection ≥ 1 asexual form / 500 white blood cells~* Informed consent (written/verbal) provided by patient or relative/legal guardian~* Signed Assent form for children aged 12 to \< 18 years~Exclusion Criteria:~* Clinical signs of severe malaria or danger signs~* Pregnant or breast feeding~* Unable or unwilling to take a pregnancy test (for women of child-bearing age)~* Women intending to become pregnant in the next 3 months~* Allergic to primaquine or DHA PP~* Patients taking drugs known to cause acute intravascular haemolytic anaemia (AIHA) in G6PD deficiency e.g. dapsone, nalidixic acid~* Patients on treatment for a significant illness e.g. HIV, tuberculosis (TB) treatment, steroids~* On drugs that could interfere with anti-malarial pharmacokinetics like antiretrovirals, cimetidine, ketoconazole, antiepileptic drugs, rifampicin

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DHA PP plus primaquine, G6PD deficiency (Type: EXPERIMENTAL): Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (\<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children \<18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (\<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets.
- DHA PP plus primaquine, G6PD normal (Type: ACTIVE_COMPARATOR): Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (\<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children \<18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (\<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets.
- DHA PP alone, G6PD deficiency (Type: ACTIVE_COMPARATOR): Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (\<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
- DHA PP alone, G6PD normal (Type: ACTIVE_COMPARATOR): Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (\<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete